272 related articles for article (PubMed ID: 19352380)
21. Fracture risk of young adults receiving proton-pump inhibitors and H2-receptor antagonists.
Fedida B; Schermann H; Ankory R; Rotman D; Shichman I; Yoffe V; Shlaifer A; Luger E
Int J Clin Pract; 2019 May; 73(5):e13339. PubMed ID: 30829427
[TBL] [Abstract][Full Text] [Related]
22. Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists.
Kweon T; Kim Y; Lee KJ; Seo WW; Seo SI; Shin WG; Shin DH
Sci Rep; 2023 Dec; 13(1):21169. PubMed ID: 38036592
[TBL] [Abstract][Full Text] [Related]
23. Prenatal exposure to acid-suppressive drugs and the risk of childhood asthma: a population-based Danish cohort study.
Andersen AB; Erichsen R; Farkas DK; Mehnert F; Ehrenstein V; Sørensen HT
Aliment Pharmacol Ther; 2012 May; 35(10):1190-8. PubMed ID: 22443179
[TBL] [Abstract][Full Text] [Related]
24. Risk of gastric cancer among long-term proton pump inhibitor users: a population-based cohort study.
Kim JW; Jung HK; Lee B; Shin CM; Gong EJ; Hong J; Youn YH; Lee KJ
Eur J Clin Pharmacol; 2023 Dec; 79(12):1699-1708. PubMed ID: 37861752
[TBL] [Abstract][Full Text] [Related]
25. Use of proton pump inhibitors for the risk of gastric cancer.
Gao H; Li L; Geng K; Teng C; Chen Y; Chu F; Zhao Y
Medicine (Baltimore); 2022 Dec; 101(49):e32228. PubMed ID: 36626449
[TBL] [Abstract][Full Text] [Related]
26. Proton pump inhibitors and risk of gastric cancer: population-based cohort study.
Abrahami D; McDonald EG; Schnitzer ME; Barkun AN; Suissa S; Azoulay L
Gut; 2022 Jan; 71(1):16-24. PubMed ID: 34226290
[TBL] [Abstract][Full Text] [Related]
27. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.
Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y
Bone; 2020 Oct; 139():115502. PubMed ID: 32593677
[TBL] [Abstract][Full Text] [Related]
28. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
29. Association Between Proton Pump Inhibitor Use and Cognitive Function in Women.
Lochhead P; Hagan K; Joshi AD; Khalili H; Nguyen LH; Grodstein F; Chan AT
Gastroenterology; 2017 Oct; 153(4):971-979.e4. PubMed ID: 28728964
[TBL] [Abstract][Full Text] [Related]
30. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
[TBL] [Abstract][Full Text] [Related]
31. Acid suppressants use and the risk of dementia: A population-based propensity score-matched cohort study.
Wu CL; Lei WY; Wang JS; Lin CE; Chen CL; Wen SH
PLoS One; 2020; 15(11):e0242975. PubMed ID: 33253311
[TBL] [Abstract][Full Text] [Related]
32. Ranitidine and Risk of Bladder and Kidney Cancer: A Population-Based Cohort Study.
Nørgaard M; Andersen IT; Heide-Jørgensen U; Erichsen R; Rees JR; Karagas MR; Sørensen HT
Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):45-50. PubMed ID: 34649959
[TBL] [Abstract][Full Text] [Related]
33. Association between proton pump inhibitors use and risk of asthma in Korea: A prevalent new-user cohort study.
Lim HJ; Oh IS; Noh Y; Yon DK; Shin JY
Medicine (Baltimore); 2024 Jan; 103(1):e36772. PubMed ID: 38181266
[TBL] [Abstract][Full Text] [Related]
34. Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies.
Babic A; Zhang X; Morales-Oyarvide V; Yuan C; Khalaf N; Khalili H; Lochhead P; Chan AT; Ogino S; Wolpin BM; Wu K; Fuchs CS; Giovannucci EL; Stampfer MJ; Ng K
Br J Cancer; 2020 Sep; 123(5):844-851. PubMed ID: 32541871
[TBL] [Abstract][Full Text] [Related]
35. Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy.
Li CM; Zhernakova A; Engstrand L; Wijmenga C; Brusselaers N
Aliment Pharmacol Ther; 2020 Feb; 51(4):410-420. PubMed ID: 31909512
[TBL] [Abstract][Full Text] [Related]
36. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis.
Trinh VQ; Shi C; Ma C
Histopathology; 2020 Dec; 77(6):865-876. PubMed ID: 32702178
[TBL] [Abstract][Full Text] [Related]
37. Proton Pump Inhibitors, But Not H2-receptor Antagonists, Are Associated With Incident Fractures Among Kidney Transplant Recipients.
Lyu B; Jorgenson MR; Hansen KE; Djamali A; Astor BC
Transplantation; 2020 Dec; 104(12):2609-2615. PubMed ID: 32058466
[TBL] [Abstract][Full Text] [Related]
38. Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study.
Brown JP; Tazare JR; Williamson E; Mansfield KE; Evans SJ; Tomlinson LA; Bhaskaran K; Smeeth L; Wing K; Douglas IJ
Br J Clin Pharmacol; 2021 Aug; 87(8):3150-3161. PubMed ID: 33393677
[TBL] [Abstract][Full Text] [Related]
39. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.
Park J; You SC; Cho J; Park CH; Shin WG; Park RW; In Seo S
BMC Pharmacol Toxicol; 2022 Jan; 23(1):9. PubMed ID: 35039078
[TBL] [Abstract][Full Text] [Related]
40. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.
Solomon DH; Diem SJ; Ruppert K; Lian YJ; Liu CC; Wohlfart A; Greendale GA; Finkelstein JS
J Bone Miner Res; 2015 Feb; 30(2):232-9. PubMed ID: 25156141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
